The Making Tracks for Celiacs Walk/Runs have raised more than $2.5 million for celiac disease research and national and local awareness initiatives.
When it comes to food, the physician-researcher is passionate about an ingredient that has fueled both his career and a national dietary fervor: gluten.
Neurologist Anne Louise Oaklander, MD, PhD, of Mass General, uses her research to identify neurological causes of mysterious symptoms, so patients can receive better treatments.
New MGH research finds that neither breastfeeding nor delayed introduction of gluten-containing foods provide significant protection against celiac disease.
At Mass General, last summer’s Ice Bucket Challenge has generated fresh opportunities for ALS researchers to develop new treatments and search for a cure.
Powered by a risk-taking strategy, the Cure Alzheimer’s Fund employs venture capital principles to spur Alzheimer’s disease research into a new era at MGH and beyond.
Researchers in the Center for Molecular Therapeutics at the Mass General Cancer Center are working to identify new combination therapies to solve the problem of acquired resistance.
Sydney Cash, MD, PhD, of Mass General is creating devices to help physicians and patients better understand and predict epilepsy-related seizures.
After Nick Cancelliere was diagnosed with an aggressive form of leukemia, his Mass General team provided a new treatment targeting one very dangerous gene.
Teaching computers to recognize patterns in data is helping physicians improve the speed and accuracy of diagnosis and further personalize patient care.